Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy

被引:10
|
作者
Zhang, Lin [1 ]
An, Xiao-Fei [2 ]
Ruan, Xin [3 ]
Huang, Dong-Dong [3 ]
Zhou, Li [4 ]
Xue, Hong [4 ]
Lu, Li-Min [4 ]
He, Ming [3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai, Peoples R China
[2] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Univ Chinese Med, Key Lab Cell Differentiat & Apoptosis, Sch Med, Chinese Minist Educ,Dept Pathophysiol, Nanjing, Jiangsu, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Physiol & Pathophysiol, Shanghai, Peoples R China
来源
FRONTIERS IN PHYSIOLOGY | 2017年 / 8卷
基金
中国国家自然科学基金;
关键词
diabetic nephropathy; renin-angiotensin system; (pro)renin receptor; angiotensin II type 1 receptor; angiotensin II type 2 receptor; RENIN/PRORENIN RECEPTOR; NONPROTEOLYTIC ACTIVATION; KIDNEY-DISEASE; RENIN; PRORENIN; LOSARTAN; SYSTEM; RATS; GLOMERULOSCLEROSIS; PHENOTYPE;
D O I
10.3389/fphys.2017.00758
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Aims: Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN). Angiotensin II (Ang II) type 1 receptor (AT1R) blockade elevates (pro)renin, which may bind to (pro)renin receptor (PRR) and exert receptor-mediated, angiotensin-independent profibrotic effects. We therefore investigated whether PRR activation leads to the limited anti-fibrotic effects of AT1R blockade on DN, and whether PRR inhibition might ameliorate progression of DN. Methods: To address the issue, the expression of RAS components was tested in different stages of streptozotocin (STZ)-induced diabetic rats (6, 12, and 24 weeks) and 6-week AT1R blockade (losartan) treated diabetic rats. Using the blocker for PRR, the handle region peptide (HRP) of prorenin, the effects of PRR on high glucose or Ang II-induced proliferative and profibrotic actions were evaluated by measurement of cell proliferation, matrix metalloproteinase-2 (MMP-2) activity, activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and transforming growth factor-beta 1 (TGF-beta 1) expression in rat mesangial cells (MCs). Results: PRR was downregulated in the kidneys of different stages of diabetic rats (6, 12, and 24 weeks). Moreover, 6-week losartan treatment further suppressed PRR expression via upregulating AT2R, and ameliorated diabetic renal injury. HRP inhibited high glucose and Ang II-induced proliferative and profibrotic effects in MCs through suppressing TGF-beta 1 expression and activating MMP-2. Meanwhile, HRP enhanced losartan's anti-fibrotic effects through further inhibiting phosphorylation of ERK1/2 and TGF-beta 1 expression. Moreover, the inhibitive effect of HRP on Ang II-induced TGF-beta 1 expression depended on the regulation of PRR expression by AT2R. Conclusions: Our findings suggest that inhibition of PRR contributes to renoprotection against diabetic nephropathy by AT1R blockade.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
    Andersen, S
    Tarnow, L
    Rossing, P
    Hansen, BV
    Parving, HH
    [J]. KIDNEY INTERNATIONAL, 2000, 57 (02) : 601 - 606
  • [2] Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen, S
    Tarnow, L
    Rossing, P
    Hansen, BV
    Parving, HH
    [J]. DIABETOLOGIA, 1999, 42 : A10 - A10
  • [3] Angiotensin II receptor blockade in diabetic nephropathy
    Ruddy, MC
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (05) : 468 - 471
  • [4] Angiotensin II receptor blockade in diabetic nephropathy
    Andersen, S
    [J]. DANISH MEDICAL BULLETIN, 2004, 51 (03) : 274 - 294
  • [5] Angiotensin II receptor blockade in diabetic nephropathy
    Lewis, EJ
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (01) : 100 - 101
  • [6] Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats
    Mizuguchi, Yuki
    Ichihara, Atsuhiro
    Seki, Yasufumi
    Sakoda, Mariyo
    Kurauchi-Mito, Asako
    Narita, Tatsuya
    Kinouchi, Kenichiro
    Bokuda, Kanako
    Itoh, Hiroshi
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (5-6) : 569 - 573
  • [7] Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy
    Jacobsen, P
    Andersen, S
    Jensen, BR
    Parving, HH
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04): : 992 - 999
  • [8] (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation
    Matavelli, Luis C.
    Huang, Jiqian
    Siragy, Helmy M.
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (03) : 277 - 282
  • [9] Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor
    Sourris, K. C.
    Morley, A. L.
    Koitka, A.
    Samuel, P.
    Coughlan, M. T.
    Penfold, S. A.
    Thomas, M. C.
    Bierhaus, A.
    Nawroth, P. P.
    Yamamoto, H.
    Allen, T. J.
    Walther, T.
    Hussain, T.
    Cooper, M. E.
    Forbes, J. M.
    [J]. DIABETOLOGIA, 2010, 53 (11) : 2442 - 2451
  • [10] Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor
    K. C. Sourris
    A. L. Morley
    A. Koitka
    P. Samuel
    M. T. Coughlan
    S. A. Penfold
    M. C. Thomas
    A. Bierhaus
    P. P. Nawroth
    H. Yamamoto
    T. J. Allen
    T. Walther
    T. Hussain
    M. E. Cooper
    J. M. Forbes
    [J]. Diabetologia, 2010, 53 : 2442 - 2451